Oliver Carpenter, Head of Environmental Analytics at Risilience, explains why integrating climate and nature risk into financial planning is essential to safeguarding growth and margins.
The pharmaceutical and healthcare sector has long operated on the assumption that nature is a stable backdrop.
Its precision-driven manufacturing, sensitive chemical formulations and global cold chains depend on predictable weather, intact ecosystems and reliable access to high-purity natural resources.
Today, accelerating climate change and biodiversity loss are fracturing that foundation, turning environmental volatility into immediate operational and balance-sheet risk.
A perfect storm: shifting pathologies and squeezed operations
Climate change is fundamentally altering the pharmaceutical demand curve.
Rising temperatures and shifting precipitation patterns are expanding the geographic footprint of vector-borne diseases such as malaria and dengue into previously unaffected regions.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
